Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Research Use Only|International Shipping|North American Made|Free Shipping $149 USD+|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Research Use Only|International Shipping|North American Made|Free Shipping $149 USD+|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Research Use Only|International Shipping|North American Made|Free Shipping $149 USD+|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Research Use Only|International Shipping|North American Made|Free Shipping $149 USD+|
All Comparisons

PT-141 vs Melanotan II

Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.

PT-141: AMelanotan II: F
AttributePT-141Melanotan II
CategorySexual HealthMelanocortin Agonist
Evidence RatingAFDA ApprovedFNo Regulatory Activity
Clinical StatusFDA-approved (Vyleesi for HSDD in premenopausal women)Research-only / Not approved. Multiple regulatory warnings issued worldwide.
MechanismPT-141 (MW ~1025 g/mol, C50H68N14O10, half-life 2-6 hours) is a synthetic analog of alpha-MSH targeting MC3R and MC4R. MC4R activation in the CNS enhances dopamine release in the nucleus accumbens and medial preoptic area, increasing sexual motivation. Subcutaneous bioavailability is approximately 1...MT-II activates melanocortin receptors MC1R through MC5R non-selectively. MC1R activation stimulates melanogenesis (skin tanning) in melanocytes. MC3R/MC4R activation in the CNS increases sexual arousal and desire via dopamine release pathways. MC4R activation centrally suppresses appetite. The non-...
Half-Life~2.5 hours~36 minutes IV; longer SC due to depot effect
Bioavailability~25% SC
Molecular Weight~1025.2 g/mol~1024.2 g/mol
WADA StatusNot ListedProhibited
Dosing1.75 mg SC per dose (FDA-approved); max 1 dose per 24 hours, max 8 doses per month, As needed, at least 45 minutes before sexual activity (Subcutaneous)Loading: 0.25–0.5 mg/day for 5–7 days; Maintenance: 0.5–1.0 mg 1–2x weekly, Daily during loading phase; 1–2x weekly maintenance (Subcutaneous)
Key Use Cases
  • Sexual Health
  • Tanning
  • Sexual Health
Safety Concerns
  • Common: nausea (~40%, most common and dose-limiting), flushing (50-70%), headache (10-25%), injection site reactions
  • Transient increases in blood pressure and heart rate; not recommended for uncontrolled hypertension or cardiovascular disease
  • Skin hyperpigmentation with repeated use (MC1R agonism); darker-skinned patients more susceptible; resolution not confirmed in all patients
  • Nausea (very common, especially at initial doses)
  • Facial flushing and warmth
  • Spontaneous erections (in males)
Contraindications
  • Uncontrolled hypertension or cardiovascular disease
  • Concurrent use with naltrexone
  • History of melanoma (caution due to melanocortin receptor activation)
  • Pregnancy and breastfeeding
  • History of melanoma or atypical moles/dysplastic nevi
  • Cardiovascular disease
  • Pregnancy and breastfeeding
  • Family history of skin cancer
Regulatory (US)FDA-approved (Vyleesi, 2019) for HSDD in premenopausal women. 1.75 mg SC on-demand, max 8 doses/month.Not FDA-approved. FDA has issued warnings against use. Removed from Category 2 on April 15, 2026. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility.

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.